Sichuan Biokin Pharmaceutical (SHA:688506) completed the enrollment of its first subject in the Phase III clinical trial on BL-M05D1 injection, according to a Shanghai bourse filing on Friday.
The drug is being tested as a treatment for patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have previously received first-line therapy.
TES (KOSDAQ:095610) secured a semiconductor manufacturing equipment contract from chipmaker SK Hynix (KRX:000660), the South Korean manufacturer of chips, solar cell, and display equipment, said in a Friday filing with the Korea Exchange.The contract, valued at 21.2 billion won, is valid until Jan. 15, 2027.Shares of SK Hynix fell nearly 7% in recent trade.
GuocoLand's (SGX:F17) Malaysia-listed unit, declined (Malaysia) (KLSE:GUOCO), filed a formal petition with the High Court of Malaysia to confirm its proposed share capital reduction and repayment framework, according to a Thursday filing.The court application, submitted on June 4, serves as the primary legal step remaining to execute the company's privatization via a selective capital reduction mechanism.This follows the property developer's shareholders approving the proposed privatization of the company at an extraordinary general meeting held on May 29.
Yangtze Optical Fibre and Cable (SHA:601869, HKG:6869) experienced an abnormal stock fluctuation for three consecutive trading days, but its operations remain normal, according to a Shanghai bourse filing on Friday.The company's closing stock price between June 2 and June 4 was more than 20%, exceeding the bourse's threshold.The company's probe found that it does not have a significant disclosure that could affect its stock movement.The Chinese cable manufacturer's Hong Kong shares jumped 5%, while Shanghai shares rose 2% during the morning trade.